Literature DB >> 12531356

Functional mapping of protective epitopes within the rotavirus VP6 protein in mice belonging to different haplotypes.

Anthony H-C Choi1, Monica M McNeal, Mitali Basu, Judy A Bean, John L VanCott, John D Clements, Richard L Ward.   

Abstract

We recently used "functional mapping" to locate protective epitopes in the carboxyl terminus (aa 197-397) of the VP6 protein (designated CD) of the EDIM strain of murine rotavirus [J. Virol. 74 (2000) 11574]. For this, H-2(d) BALB/c mice were given two intranasal (i.n.) immunizations (separated by 2 weeks) with VP6 or CD genetically-fused to maltose-binding protein, or with overlapping synthetic CD peptides, along with LT(R192G), a genetically-attenuated E. coli heat-labile toxin. The protective efficacies, i.e., percentage reductions in rotavirus shedding relative to control mice during 7 days following oral challenge with EDIM, were determined 4 weeks after the second immunization. Five of the 11 overlapping CD peptides stimulated significant protection (57-85%, P<0.05). Furthermore, chimeric VP6, the CD fragment, and a 14-amino-acid VP6 peptide within CD (RLSFQLMRPPNMTP), identified as a H-2(d)-restricted CD4 T cell epitope, were highly protective (93-98%, P<0.05). In this study, we continued to utilize functional mapping to show that the 14-mer peptide elicited significant protection (97.0%, P<0.05) in another H-2(d) mouse strain (DBA/2) but partial protection in H-2(b) 129 (39.2%) and C57Bl/6 (53.6%) as well as H-2(k) C3H (44.6%) mice. The first 13 amino acids of this 14-mer were necessary to induce maximal protection in H-2(d) mice. In addition, the H-2(b) 129 mice were immunized intranasally (i.n.) with 10 of the synthetic CD peptides and 5 were found to induce significant protection (90-97%, P<0.05). We also performed functional mapping to identify MHC class I epitopes in rotavirus proteins. A class I-binding epitope for H-2(b) C57Bl/6 mice had previously been mapped by ex vivo CTL assays within the VP6 protein and two additional class I epitopes were identified by computer-based prediction. When examined for their protective efficacies by functional mapping, two of the three were found to be partially but not significantly protective (44 and 46%, P>0.05). To better determine the usefulness of our in vivo methods to identify MHC class I-binding epitopes, four epitopes from the outer capsid VP7 rotavirus protein determined in ex vivo assays were evaluated for their protective efficacies and two were found to be partially protective. Together, these studies show that functional mapping is useful in locating epitopes that are relevant to the development of subunit rotavirus vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531356     DOI: 10.1016/s0264-410x(02)00595-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Norovirus P particle, a novel platform for vaccine development and antibody production.

Authors:  Ming Tan; Pengwei Huang; Ming Xia; Ping-An Fang; Weiming Zhong; Monica McNeal; Chao Wei; Wen Jiang; Xi Jiang
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

2.  Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effector protein provides protection against lethal infection.

Authors:  Jonathan R Kurtz; Hailey E Petersen; Daniel R Frederick; Lisa A Morici; James B McLachlan
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Authors:  Audrey Glynn; Chad J Roy; Bradford S Powell; Jeffrey J Adamovicz; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.

Authors:  Ming Xia; Pengwei Huang; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2019-06-11       Impact factor: 3.641

5.  Cellular and humoral immunity following Snow Mountain virus challenge.

Authors:  Lisa Lindesmith; Christine Moe; Jacques Lependu; Jeffrey A Frelinger; John Treanor; Ralph S Baric
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

7.  Peptide-Recombinant VP6 Protein Based Enzyme Immunoassay for the Detection of Group A Rotaviruses in Multiple Host Species.

Authors:  Naveen Kumar; Yashpal Singh Malik; Satish Kumar; Kuldeep Sharma; Subhankar Sircar; Sharad Saurabh; Baldev R Gulati; Neeraj Singh; Arvind Kumar Singh; Vinay G Joshi; Krisztian Banyai; Kuldeep Dhama
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

Review 8.  Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.

Authors:  Zabihollah Shoja; Somayeh Jalilvand; Tayebeh Latifi; Farzin Roohvand
Journal:  Arch Virol       Date:  2022-03-15       Impact factor: 2.685

9.  Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa.

Authors:  Elisabeth Heylen; Mark Zeller; Max Ciarlet; Jody Lawrence; Duncan Steele; Marc Van Ranst; Jelle Matthijnssens
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

Review 10.  Preparation of recombinant vaccines.

Authors:  Eric Soler; Louis-Marie Houdebine
Journal:  Biotechnol Annu Rev       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.